Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
US FDA Accepts Takeda’s Rusfertide Filing, Grants Priority Review
Takeda Pharmaceutical and Protagonist Therapeutics said on March 2 that the US FDA has accepted a new drug application for rusfertide, an investigational treatment for polycythemia vera (PV), under a priority review pathway. The FDA set a target action date…
To read the full story
Related Article
- Takeda Files Polycythemia Vera Drug Rusfertide in US
January 7, 2026
- Takeda on Course to Stable Growth as Late-Stage Assets Near Market
May 9, 2025
- Protagonist/Takeda’s Hematology Med Makes Mark in PIII
March 5, 2025
- Takeda Sees Up to US$20 Billion Sales Potential with 6 Late-Stage Assets
December 16, 2024
- Takeda Bags Global Rights to Protagonist’s Rare Hematology Asset
February 2, 2024
BUSINESS
- Kowa Wins Hong Kong Approval for Livalo, Glanatec OK in Vietnam
July 3, 2026
- Medinet Exercises Option for Stempeucel Rights in Japan
July 3, 2026
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…